JP2013522239A - 注射用薬物送達システム - Google Patents

注射用薬物送達システム Download PDF

Info

Publication number
JP2013522239A
JP2013522239A JP2012557295A JP2012557295A JP2013522239A JP 2013522239 A JP2013522239 A JP 2013522239A JP 2012557295 A JP2012557295 A JP 2012557295A JP 2012557295 A JP2012557295 A JP 2012557295A JP 2013522239 A JP2013522239 A JP 2013522239A
Authority
JP
Japan
Prior art keywords
polysaccharide
formulation
group
api
glucopyranose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012557295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522239A5 (enExample
Inventor
ティモシー エム． クロケ，
ジョラン スレイガー，
ラクシュマ ガンドラパリー レディー，
デイビッド イー． バブコック，
Original Assignee
サーモディクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サーモディクス，インコーポレイテッド filed Critical サーモディクス，インコーポレイテッド
Publication of JP2013522239A publication Critical patent/JP2013522239A/ja
Publication of JP2013522239A5 publication Critical patent/JP2013522239A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
JP2012557295A 2010-03-12 2011-03-11 注射用薬物送達システム Pending JP2013522239A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31366610P 2010-03-12 2010-03-12
US61/313,666 2010-03-12
PCT/US2011/028195 WO2011112996A2 (en) 2010-03-12 2011-03-11 Injectable drug delivery system

Publications (2)

Publication Number Publication Date
JP2013522239A true JP2013522239A (ja) 2013-06-13
JP2013522239A5 JP2013522239A5 (enExample) 2014-04-24

Family

ID=44148866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012557295A Pending JP2013522239A (ja) 2010-03-12 2011-03-11 注射用薬物送達システム

Country Status (5)

Country Link
US (1) US20110229457A1 (enExample)
EP (1) EP2544658A2 (enExample)
JP (1) JP2013522239A (enExample)
CA (1) CA2792771A1 (enExample)
WO (1) WO2011112996A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613413A1 (en) * 2011-12-05 2020-02-26 Incept, LLC Medical organogel processes and compositions
AU2013355043A1 (en) * 2012-12-06 2015-07-02 Tobira Therapeutics, Inc. Oligonucleotide formulation
CN106573133B (zh) 2014-08-19 2020-03-03 加利福尼亚大学董事会 用于局部药物递送的植入物及其使用方法
US20180371158A1 (en) * 2015-12-18 2018-12-27 Abraham Joy Peptidomimetic polymers as controlled release matrices for small molecules, biologicals, synthetic or semi-synthetic macromolecules
JP7054793B2 (ja) * 2017-07-07 2022-04-15 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
JP6952279B2 (ja) * 2017-07-07 2021-10-20 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
JP7054792B2 (ja) * 2017-07-07 2022-04-15 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
CN110537098B (zh) * 2017-07-07 2022-01-25 松下知识产权经营株式会社 信息提供方法、信息处理系统、信息终端及信息处理方法
JP6924969B2 (ja) * 2017-07-07 2021-08-25 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
JP7487220B2 (ja) * 2019-03-05 2024-05-20 ダウ グローバル テクノロジーズ エルエルシー カスパーゼ活性を誘導するためのポリエチレングリコール誘導体
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
CN111956638B (zh) * 2020-08-06 2023-01-24 上海宛文创业孵化器管理合伙企业(有限合伙) 蓓萨罗丁或/和其药学上可接受的盐在制备抗肺动脉高压药物中的应用
WO2023056447A1 (en) 2021-10-01 2023-04-06 Promega Corporation Compounds and methods for detection of nitric oxide
CN116870238A (zh) * 2023-08-25 2023-10-13 中国海洋大学 一种抑菌介孔淀粉止血粉及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001509146A (ja) * 1996-12-20 2001-07-10 アルザ コーポレイション ゲル組成物および方法
JP2004511431A (ja) * 2000-06-28 2004-04-15 アトゥル・ジェイ・シュクラ 生物活性物質を含む生分解性ビヒクルおよび送達システム
JP2008501757A (ja) * 2004-06-09 2008-01-24 ノバルティス アクチエンゲゼルシャフト ６００ダルトン未満の分子量を有するポリエチレングリコールを含む医薬組成物
JP2008524235A (ja) * 2004-12-15 2008-07-10 キューエルティー ユーエスエー，インコーポレイテッド． オクトレオチド化合物の徐放性送達処方物
JP2009529967A (ja) * 2006-03-15 2009-08-27 サーモディクス，インコーポレイティド 天然生分解性ポリサッカライドの疎水性誘導体及びそれらの使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4433101A1 (de) * 1994-09-16 1996-03-21 Bauer Kurt Heinz Prof Dr Wasserlösliche Dextranfettsäureester und ihre Verwendung als Solubilisatoren
US6224893B1 (en) * 1997-04-11 2001-05-01 Massachusetts Institute Of Technology Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
US6472512B1 (en) * 1998-07-21 2002-10-29 Human Genome Sciences, Inc. Keratinocyte derived interferon
EP1481695A1 (en) * 1999-10-15 2004-12-01 Genetics Institute, LLC Formulations of hyaluronic acid for delivery of osteogenic proteins
US6703040B2 (en) 2000-01-11 2004-03-09 Intralytix, Inc. Polymer blends as biodegradable matrices for preparing biocomposites
CA2494241C (en) * 2000-02-08 2011-06-14 Allergan, Inc. Botulinum toxin pharmaceutical compositions
JP4817088B2 (ja) * 2000-10-10 2011-11-16 株式会社林原生物化学研究所 塞栓材料
IL159048A0 (en) * 2001-06-21 2004-05-12 Genentech Inc Sustained release formulation
JP4624678B2 (ja) * 2002-02-21 2011-02-02 パイオニア・サージカル・オーソバイオロジックス，インコーポレイテッド 架橋生物活性ヒドロゲルマトリックス
EP1555278A1 (en) 2004-01-15 2005-07-20 Innocore Technologies B.V. Biodegradable multi-block co-polymers
DE102004021240B4 (de) * 2004-04-30 2008-07-31 Infineon Technologies Ag Verfahren zur Herstellung einer Halbleiter-Schaltungsanordnung in BiCMOS-Technologie
US20090022805A1 (en) * 2007-06-28 2009-01-22 Joram Slager Polypeptide microparticles having sustained release characteristics, methods and uses
WO2010141553A1 (en) * 2009-06-02 2010-12-09 Surmodics, Inc. SILANE-FUNCTIONALIZED HYDROPHOBIC a(1→4)GLUCOPYRANOSE POLYMERS AND POLYMERIC MATRICES FOR IMPLANTATION OR INJECTION

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001509146A (ja) * 1996-12-20 2001-07-10 アルザ コーポレイション ゲル組成物および方法
JP2004511431A (ja) * 2000-06-28 2004-04-15 アトゥル・ジェイ・シュクラ 生物活性物質を含む生分解性ビヒクルおよび送達システム
JP2008501757A (ja) * 2004-06-09 2008-01-24 ノバルティス アクチエンゲゼルシャフト ６００ダルトン未満の分子量を有するポリエチレングリコールを含む医薬組成物
JP2008524235A (ja) * 2004-12-15 2008-07-10 キューエルティー ユーエスエー，インコーポレイテッド． オクトレオチド化合物の徐放性送達処方物
JP2009529967A (ja) * 2006-03-15 2009-08-27 サーモディクス，インコーポレイティド 天然生分解性ポリサッカライドの疎水性誘導体及びそれらの使用

Also Published As

Publication number Publication date
WO2011112996A2 (en) 2011-09-15
US20110229457A1 (en) 2011-09-22
EP2544658A2 (en) 2013-01-16
WO2011112996A3 (en) 2011-11-10
CA2792771A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
JP2013522239A (ja) 注射用薬物送達システム
Li et al. Biodegradable and injectable hydrogels in biomedical applications
Kim et al. Natural and synthetic biomaterials for controlled drug delivery
Ruel-Gariepy et al. Characterization of thermosensitive chitosan gels for the sustained delivery of drugs
Prabaharan et al. Chitosan-based particles as controlled drug delivery systems
US9205046B2 (en) Enhanced stability of inverse thermal gelling composite hydrogels
Villanueva et al. Dendrimers as a promising tool in ocular therapeutics: Latest advances and perspectives
Bader et al. Polysialic acid-based micelles for encapsulation of hydrophobic drugs
Aminabhavi et al. Production of chitosan-based hydrogels for biomedical applications
WO2007135164A1 (en) Nanoparticles of chitosan and hyaluronan for the administration of active molecules
WO2008136536A1 (ja) 化学架橋ヒアルロン酸誘導体を含むハイブリッドゲルおよびそれを用いた医薬組成物
Bos et al. Tissue reactions of in situ formed dextran hydrogels crosslinked by stereocomplex formation after subcutaneous implantation in rats
CA2703807A1 (en) Enhanced stability of inverse thermal gelling composite hydrogels
US20100260846A1 (en) Particles for delivery of nucleic acids and related devices and methods
JP2013530235A (ja) 核酸の送達を向上させるための組成物および方法
US9949928B2 (en) Biodegradable copolymers, systems including the copolymers, and methods of forming and using same
Biswas et al. Polymers and their engineered analogues for ocular drug delivery: enhancing therapeutic precision
EP1891941A1 (en) Aqueous gels comprising microspheres
Siafaka et al. Polymer based gels: Recent and future applications in drug delivery field
CN101448489A (zh) 用于活性分子给药的壳聚糖和乙酰透明质酸的纳米颗粒
US8697105B2 (en) Injectable drug delivery formulation
Shi et al. Injectable long-acting systems for Radix Ophiopogonis polysaccharide based on mono-PEGylation and in situ formation of a PLGA depot
Moscovici1 et al. Nanocellulose and nanogels as modern drug delivery systems
Vora et al. Injectable depot-forming hydrogels for long-acting drug delivery
Moscovici et al. Bacterial polysaccharides versatile medical uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151006